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Background
Chronic HBV and HCV infections are common co-mor-
bidities that can complicate antiretroviral treatment in
HIV-infected patients. Information on efficacy and safety
are necessary to better define optimal therapeutic options
in this population.
Methods
Randomized, open-label prospective study comparing
once-daily ATV/r with twice-daily LPV/r, both in combi-
nation with once-daily fixed dose combination tenofovir/
emtricitabine in antiretroviral-naive HIV-1 infected sub-
jects. Proportion of subjects with HIV RNA <50 c/mL
(confirmed virologic response/CVR), changes in CD4 cell
count and lipids from baseline, and adverse events (AEs)
through 48 weeks are presented among chronic HBV-
and/or HCV-infected (Hep+) subjects.
Summary of results
At baseline, 13% of subjects were Hep+ (5% HBV+; 8%
HCV+). Overall 9% of females, 14% males, 25% Asians,
15% Blacks, 5% others, and 13% of Whites were Hep+.
(Table 1.)
Grade 2–4 treatment related hyperbilirubinemia (15% vs.
0) and jaundice (3% vs. 0) were more common on ATV/r.
Nausea (8% vs. 2%) and diarrhea (14% vs. 0) were more
common on LPV/r. Few SAEs were reported among Hep+
in either treatment arm. Grade 3–4 elevations in liver
function tests were reported among the following: 5/60,
8% (ALT), 5/60, 8% (AST) and 23/60, 38% (total
bilirubin) in the ATV/r arm and 3/50, 6% (ALT), 0%
(AST); 0% (total bilirubin) in the LPV/r arm. (Table 2.)
Conclusion
Virologic and immunologic response was comparable in
Hep+ treated with ATV/r or LPV/r. ATV/r had a more favo-
rable lipid profile (TC, non-HDL, LDL, TG) and fewer gas-
trointestinal adverse events among Hep+ subjects than
LPV/r. While the overall rates of transaminitis in Hep+
were low in this study compared to those observed in
other clinical trials, a small number of subjects in the ATV/
r and none on LPV/r had grade 3–4 AST elevations. The
cause of this higher proportion in the ATV/r treatment
arm among this limited number of subjects is unclear.
With close monitoring of liver function tests, ATV/r can be
considered as part of HAART among treatment-naive
Hep+ patients.
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Table 1: 
Efficacy at Week 48 ATV/r N = 61 LPV/r N = 51
HIV RNA<50 c/mL, CVR (Non-
Completer = Failure), n/N (%)
42/61 (69) 37/51 (73)
Mean CD4 Cell Count Change from 
Baseline (SE), cells/mm3
196 (26.1) 228 (21.7)
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Table 2: Lipid Mean % Change (+/- SE) from Baseline at Week 48 
– As Treated Subjects
ATV/r N = 60 LPV/r N= 51
Total Cholesterol (TC) 12 (9.4, 15.3) 23 (20.1, 26.4)
HDL 28 (24.2, 32.4) 42 (32.3, 53.1)
Non-HDL 7 (3.1, 10.9) 17 (14.2, 20.9)
LDL 12 (6.4, 16.9) 21 (14.6, 27.8)
Triglycerides (TG) 18 (9.8, 27.1) 45 (33.2, 58.2)
